RegASK, a global RegTech SaaS firm, has raised $10m in a Series A funding round led by Monograph Capital.
The round was joined by SPRIM Global Investments alongside a slew of other different investors.
RegASK claims it makes regulatory information relevant, curated and easy to access for businesses, enabling them to cut through the clutter and complexity of an ever-growing number of new regulations.
The firm uses AI to stay ahead of the fast-changing regulatory environment. RegASK’s technology platform routinely monitors, curates and automatically summarizes regulations around the globe for biopharma, CROs, consumer health, medical device and food companies.
The platform further provides in-depth insights into regulations and pending regulatory changes, and connects businesses with over 400+ subject matter experts in 100+ countries for strategy and planning.
RegASK will use the funding to further invest in the platform and bring the company to all companies seeking to strengthen their regulatory capabilities around the globe.
The funding follows on the heels of the expansion of RegASK platform to serve new industries including biopharma and decentralized clinical trials regulation, in addition to the existing deployment in consumer health, medtech, and food industries.
RegASK CEO Caroline Shleifer said, “The addition of Monograph Capital is strategic to RegASK’s development roadmap. RegASK AI-powered platform offers companies an innovative and user-friendly solution to reduce their regulatory monitoring and compliance burdens. Monograph’s leadership brings deep industry understanding of the needs of life science and CRO companies.”
Copyright © 2022 RegTech Analyst
Copyright © 2018 RegTech Analyst
